Compile Data Set for Download or QSAR

Found 2380 hits with Last Name = 'karki' and Initial = 'r'   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410256 ((rac)-N-(3-(1,2,4,4a,5,6-hexahydro-[1,4]oxazino[4,...) Show SMILES CO[C@@H]1C[C@H]2COCCN2c2cc(ccc12)-c1cc(NC(=O)c2ccnc(c2)C(C)(F)F)cnc1C |r| Show InChI InChI=1S/C27H28F2N4O3/c1-16-22(12-19(14-31-16)32-26(34)18-6-7-30-25(11-18)27(2,28)29)17-4-5-21-23(10-17)33-8-9-36-15-20(33)13-24(21)35-3/h4-7,10-12,14,20,24H,8-9,13,15H2,1-3H3,(H,32,34)/t20-,24+/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410352 (US10377770, Example 112) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cnc2NC(=O)C3COCCN3c2c1 Show InChI InChI=1S/C24H20F3N5O3/c1-13-2-3-16(30-22(33)14-4-5-28-20(9-14)24(25,26)27)10-17(13)15-8-18-21(29-11-15)31-23(34)19-12-35-7-6-32(18)19/h2-5,8-11,19H,6-7,12H2,1H3,(H,30,33)(H,29,31,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<0.00200	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410350 (US10377770, Example 110) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cnc2C(=O)CC3COCCN3c2c1 Show InChI InChI=1S/C25H21F3N4O3/c1-14-2-3-17(31-24(34)15-4-5-29-22(9-15)25(26,27)28)10-19(14)16-8-20-23(30-12-16)21(33)11-18-13-35-7-6-32(18)20/h2-5,8-10,12,18H,6-7,11,13H2,1H3,(H,31,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00200	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410384 (US10377770, Example 144) Show SMILES Cc1ccc(NC(=O)c2cncc(c2)C(F)(F)F)cc1-c1cnc2C(O)CC3COCCN3c2c1 Show InChI InChI=1S/C25H23F3N4O3/c1-14-2-3-18(31-24(34)16-6-17(12-29-10-16)25(26,27)28)8-20(14)15-7-21-23(30-11-15)22(33)9-19-13-35-5-4-32(19)21/h2-3,6-8,10-12,19,22,33H,4-5,9,13H2,1H3,(H,31,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00200	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410277 ((rac)-N-(3-(6-hydroxy-6-methyl-1,2,4,4a,5,6-hexahy...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cnc2c(c1)N1CCOCC1C[C@@]2(C)O |r| Show InChI InChI=1S/C26H25F3N4O3/c1-15-3-4-18(32-24(34)16-5-6-30-22(10-16)26(27,28)29)11-20(15)17-9-21-23(31-13-17)25(2,35)12-19-14-36-8-7-33(19)21/h3-6,9-11,13,19,35H,7-8,12,14H2,1-2H3,(H,32,34)/t19?,25-/m1/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00200	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410356 (US10377770, Example 116 | rac-trans-2-(1,1-Difluor...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1cnc2CC(CO)C3COCCN3c2c1 Show InChI InChI=1S/C27H28F2N4O3/c1-16-3-4-20(32-26(35)17-5-6-30-25(11-17)27(2,28)29)12-21(16)18-10-23-22(31-13-18)9-19(14-34)24-15-36-8-7-33(23)24/h3-6,10-13,19,24,34H,7-9,14-15H2,1-2H3,(H,32,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<0.00200	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410342 (N-(3-((4aR,6R)-6-Hydroxy-1,2,4,4a,5,6-hexahydro-[1...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cnc2[C@H](O)C[C@@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C25H23F3N4O3/c1-14-2-3-17(31-24(34)15-4-5-29-22(9-15)25(26,27)28)10-19(14)16-8-20-23(30-12-16)21(33)11-18-13-35-7-6-32(18)20/h2-5,8-10,12,18,21,33H,6-7,11,13H2,1H3,(H,31,34)/t18-,21-/m1/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	<0.00200	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410387 (US10377770, Example 147) Show SMILES Cc1ccc(NC(=O)c2cc(ccn2)C(F)(F)F)cc1-c1cnc2C(O)CC3COCCN3c2c1 Show InChI InChI=1S/C25H23F3N4O3/c1-14-2-3-17(31-24(34)20-9-16(4-5-29-20)25(26,27)28)10-19(14)15-8-21-23(30-12-15)22(33)11-18-13-35-7-6-32(18)21/h2-5,8-10,12,18,22,33H,6-7,11,13H2,1H3,(H,31,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00300	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410381 (US10377770, Example 141) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(C)F)cc1-c1cnc2C(O)CC3COCCN3c2c1 Show InChI InChI=1S/C27H29FN4O3/c1-16-4-5-19(31-26(34)17-6-7-29-24(11-17)27(2,3)28)12-21(16)18-10-22-25(30-14-18)23(33)13-20-15-35-9-8-32(20)22/h4-7,10-12,14,20,23,33H,8-9,13,15H2,1-3H3,(H,31,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00400	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410351 (US10377770, Example 111) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cnc2c(c1)N1CCOCC1CC2(F)F Show InChI InChI=1S/C25H21F5N4O2/c1-14-2-3-17(33-23(35)15-4-5-31-21(9-15)25(28,29)30)10-19(14)16-8-20-22(32-12-16)24(26,27)11-18-13-36-7-6-34(18)20/h2-5,8-10,12,18H,6-7,11,13H2,1H3,(H,33,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00500	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410357 (2-(1,1-Difluoroethyl)-N-(3-((4aR,5R)-5-(hydroxymet...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1cnc2C[C@@H](CO)[C@@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C27H28F2N4O3/c1-16-3-4-20(32-26(35)17-5-6-30-25(11-17)27(2,28)29)12-21(16)18-10-23-22(31-13-18)9-19(14-34)24-15-36-8-7-33(23)24/h3-6,10-13,19,24,34H,7-9,14-15H2,1-2H3,(H,32,35)/t19-,24-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00500	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410231 ((trans)-2-(1,1-difluoroethyl)-N-(3-(6-hydroxy-1,2,...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1ccc2[C@@H](O)C[C@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C27H27F2N3O3/c1-16-3-5-19(31-26(34)18-7-8-30-25(12-18)27(2,28)29)13-22(16)17-4-6-21-23(11-17)32-9-10-35-15-20(32)14-24(21)33/h3-8,11-13,20,24,33H,9-10,14-15H2,1-2H3,(H,31,34)/t20-,24-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00500	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410362 (US10377770, Example 122 | rac-trans-N-(3-(5-(Hydro...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cnc2C[C@@H](CO)C3COCCN3c2c1 |r| Show InChI InChI=1S/C26H25F3N4O3/c1-15-2-3-19(32-25(35)16-4-5-30-24(10-16)26(27,28)29)11-20(15)17-9-22-21(31-12-17)8-18(13-34)23-14-36-7-6-33(22)23/h2-5,9-12,18,23,34H,6-8,13-14H2,1H3,(H,32,35)/t18-,23?/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00500	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410363 (US10377770, Example 123 | rac-trans-N-(3-(5-(Hydro...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cnc2C[C@H](CO)C3COCCN3c2c1 |r| Show InChI InChI=1S/C26H25F3N4O3/c1-15-2-3-19(32-25(35)16-4-5-30-24(10-16)26(27,28)29)11-20(15)17-9-22-21(31-12-17)8-18(13-34)23-14-36-7-6-33(22)23/h2-5,9-12,18,23,34H,6-8,13-14H2,1H3,(H,32,35)/t18-,23?/m1/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00500	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410358 (2-(1,1-Difluoroethyl)-N-(3-((4aR,5R)-5-(hydroxymet...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1cnc2C[C@H](CO)[C@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C27H28F2N4O3/c1-16-3-4-20(32-26(35)17-5-6-30-25(11-17)27(2,28)29)12-21(16)18-10-23-22(31-13-18)9-19(14-34)24-15-36-8-7-33(23)24/h3-6,10-13,19,24,34H,7-9,14-15H2,1-2H3,(H,32,35)/t19-,24-/m1/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00500	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410393 (US10377770, Example 153) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cnc2CC3(COC3)C3COCCN3c2c1 Show InChI InChI=1S/C27H25F3N4O3/c1-16-2-3-19(33-25(35)17-4-5-31-23(9-17)27(28,29)30)10-20(16)18-8-22-21(32-12-18)11-26(14-37-15-26)24-13-36-7-6-34(22)24/h2-5,8-10,12,24H,6-7,11,13-15H2,1H3,(H,33,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00500	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410207 ((trans)-N-(3-(6-hydroxy-1,2,4,4a,5,6-hexahydro-[1,...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1ccc2[C@@H](O)C[C@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C26H24F3N3O3/c1-15-2-4-18(31-25(34)17-6-7-30-24(11-17)26(27,28)29)12-21(15)16-3-5-20-22(10-16)32-8-9-35-14-19(32)13-23(20)33/h2-7,10-12,19,23,33H,8-9,13-14H2,1H3,(H,31,34)/t19-,23-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00600	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410306 (2-(1,1-difluoroethyl)-N-(3-(5-(hydroxymethyl)-1,2,...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1ccc2C[C@H](CO)[C@@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C27H26F3N3O3/c1-16-2-5-21(32-26(35)19-6-7-31-25(12-19)27(28,29)30)13-22(16)17-3-4-18-10-20(14-34)24-15-36-9-8-33(24)23(18)11-17/h2-7,11-13,20,24,34H,8-10,14-15H2,1H3,(H,32,35)/t20-,24+/m1/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00600	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410293 (N-(3-(5,5-bis(hydroxymethyl)-1,2,4,4a,5,6-hexahydr...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1ccc2CC(CO)(CO)[C@@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C29H31F2N3O4/c1-18-3-6-22(33-27(37)20-7-8-32-25(12-20)28(2,30)31)13-23(18)19-4-5-21-14-29(16-35,17-36)26-15-38-10-9-34(26)24(21)11-19/h3-8,11-13,26,35-36H,9-10,14-17H2,1-2H3,(H,33,37)/t26-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00600	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410349 (US10377770, Example 109) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1cnc2[C@@H](O)C[C@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C26H26F2N4O3/c1-15-3-4-18(31-25(34)16-5-6-29-23(10-16)26(2,27)28)11-20(15)17-9-21-24(30-13-17)22(33)12-19-14-35-8-7-32(19)21/h3-6,9-11,13,19,22,33H,7-8,12,14H2,1-2H3,(H,31,34)/t19-,22-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00600	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410223 (US10377770, Example 12) Show SMILES Cc1ncc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1-c1ccc2C(O)CC3COCCN3c2c1 Show InChI InChI=1S/C29H30N4O3/c1-18-25(19-7-8-24-26(12-19)33-9-10-36-16-23(33)14-27(24)34)13-22(15-31-18)32-28(35)20-5-4-6-21(11-20)29(2,3)17-30/h4-8,11-13,15,23,27,34H,9-10,14,16H2,1-3H3,(H,32,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00700	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410399 (US10377770, Example 159) Show SMILES Cc1ccc(NC(=O)c2cc(ccn2)C(F)(F)F)cc1-c1cnc2CC(CO)(CO)C3COCCN3c2c1 Show InChI InChI=1S/C27H27F3N4O4/c1-16-2-3-19(33-25(37)21-9-18(4-5-31-21)27(28,29)30)10-20(16)17-8-23-22(32-12-17)11-26(14-35,15-36)24-13-38-7-6-34(23)24/h2-5,8-10,12,24,35-36H,6-7,11,13-15H2,1H3,(H,33,37)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00700	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410353 (US10377770, Example 113) Show SMILES CCN1C(=O)C2COCCN2c2cc(cnc12)-c1cc(NC(=O)c2ccnc(c2)C(F)(F)F)ccc1C Show InChI InChI=1S/C26H24F3N5O3/c1-3-33-23-20(34-8-9-37-14-21(34)25(33)36)10-17(13-31-23)19-12-18(5-4-15(19)2)32-24(35)16-6-7-30-22(11-16)26(27,28)29/h4-7,10-13,21H,3,8-9,14H2,1-2H3,(H,32,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00800	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410281 (US10377770, Example 43 | US10377770, Example 44) Show SMILES Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc2c(c1)N1CCOCC1CC2(C)O Show InChI InChI=1S/C26H25F3N4O3/c1-15-21(10-19(13-30-15)32-24(34)16-4-3-5-18(8-16)26(27,28)29)17-9-22-23(31-12-17)25(2,35)11-20-14-36-7-6-33(20)22/h3-5,8-10,12-13,20,35H,6-7,11,14H2,1-2H3,(H,32,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00800	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410268 ((trans)-N-(3-(6-methoxy-1,2,4,4a,5,6-hexahydro-[1,...) Show SMILES COC1CC2COCCN2c2cc(cnc12)-c1cc(NC(=O)c2ccnc(c2)C(C)(F)F)ccc1C Show InChI InChI=1S/C27H28F2N4O3/c1-16-4-5-19(32-26(34)17-6-7-30-24(11-17)27(2,28)29)12-21(16)18-10-22-25(31-14-18)23(35-3)13-20-15-36-9-8-33(20)22/h4-7,10-12,14,20,23H,8-9,13,15H2,1-3H3,(H,32,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00800	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410274 ((rac)-(cis)-N-(3-(6-hydroxy-1,2,4,4a,5,6-hexahydro...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cnc2C(O)CC3COCCN3c2c1 Show InChI InChI=1S/C25H23F3N4O3/c1-14-2-3-17(31-24(34)15-4-5-29-22(9-15)25(26,27)28)10-19(14)16-8-20-23(30-12-16)21(33)11-18-13-35-7-6-32(18)20/h2-5,8-10,12,18,21,33H,6-7,11,13H2,1H3,(H,31,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00800	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410383 (US10377770, Example 143) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(C)F)cc1-c1cnc2[C@@H](O)C[C@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C27H29FN4O3/c1-16-4-5-19(31-26(34)17-6-7-29-24(11-17)27(2,3)28)12-21(16)18-10-22-25(30-14-18)23(33)13-20-15-35-9-8-32(20)22/h4-7,10-12,14,20,23,33H,8-9,13,15H2,1-3H3,(H,31,34)/t20-,23-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00900	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410380 (US10377770, Example 140) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1cnc2C(O)C(F)C3COCCN3c2c1 Show InChI InChI=1S/C26H25F3N4O3/c1-14-3-4-17(32-25(35)15-5-6-30-21(10-15)26(2,28)29)11-18(14)16-9-19-23(31-12-16)24(34)22(27)20-13-36-8-7-33(19)20/h3-6,9-12,20,22,24,34H,7-8,13H2,1-2H3,(H,32,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00900	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410361 (N-(5-((4aR,5R)-5-(Hydroxymethyl)-1,2,4,4a,5,6-hexa...) Show SMILES Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc2C[C@H](CO)[C@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C26H25F3N4O3/c1-15-21(10-20(12-30-15)32-25(35)16-3-2-4-19(7-16)26(27,28)29)17-9-23-22(31-11-17)8-18(13-34)24-14-36-6-5-33(23)24/h2-4,7,9-12,18,24,34H,5-6,8,13-14H2,1H3,(H,32,35)/t18-,24-/m1/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00900	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410300 ((rac)-N-(3-(5-(hydroxymethyl)-1,2,4,4a,5,6-hexahyd...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1ccc2CC(CO)C3COCCN3c2c1 Show InChI InChI=1S/C27H26F3N3O3/c1-16-2-5-21(32-26(35)19-6-7-31-25(12-19)27(28,29)30)13-22(16)17-3-4-18-10-20(14-34)24-15-36-9-8-33(24)23(18)11-17/h2-7,11-13,20,24,34H,8-10,14-15H2,1H3,(H,32,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00900	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410269 (US10377770, Example 34) Show SMILES COC1CC2COCCN2c2cc(cnc12)-c1cc(NC(=O)c2ccnc(c2)C(F)(F)F)ccc1C Show InChI InChI=1S/C26H25F3N4O3/c1-15-3-4-18(32-25(34)16-5-6-30-23(10-16)26(27,28)29)11-20(15)17-9-21-24(31-13-17)22(35-2)12-19-14-36-8-7-33(19)21/h3-6,9-11,13,19,22H,7-8,12,14H2,1-2H3,(H,32,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00900	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410364 (US10377770, Example 124) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1cnc2NC(=O)CC3COCCN3c2c1 Show InChI InChI=1S/C26H25F2N5O3/c1-15-3-4-18(31-25(35)16-5-6-29-22(10-16)26(2,27)28)11-20(15)17-9-21-24(30-13-17)32-23(34)12-19-14-36-8-7-33(19)21/h3-6,9-11,13,19H,7-8,12,14H2,1-2H3,(H,31,35)(H,30,32,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.00900	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410398 (US10377770, Example 158) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1cnc2CC(CO)(CO)C3COCCN3c2c1 Show InChI InChI=1S/C28H30F2N4O4/c1-17-3-4-20(33-26(37)18-5-6-31-24(10-18)27(2,29)30)11-21(17)19-9-23-22(32-13-19)12-28(15-35,16-36)25-14-38-8-7-34(23)25/h3-6,9-11,13,25,35-36H,7-8,12,14-16H2,1-2H3,(H,33,37)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410359 (US10377770, Example 119 | rac-trans-N-(5-(5-(Hydro...) Show SMILES Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc2CC(CO)C3COCCN3c2c1 Show InChI InChI=1S/C26H25F3N4O3/c1-15-21(10-20(12-30-15)32-25(35)16-3-2-4-19(7-16)26(27,28)29)17-9-23-22(31-11-17)8-18(13-34)24-14-36-6-5-33(23)24/h2-4,7,9-12,18,24,34H,5-6,8,13-14H2,1H3,(H,32,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
Complement factor B (Homo sapiens (Human))	BDBM160475 (US10093663, Example 26b | US9682968, Example-26a) Show SMILES CCO[C@H]1CCN(Cc2c(OC)cc(C)c3[nH]ccc23)[C@@H](C1)c1ccc(cc1)C(O)=O |r| Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	Purchase MCE PC cid PC sid PDB UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...				US Patent US9682968 (2017) BindingDB Entry DOI: 10.7270/Q2XG9P9J
					More data for this Ligand-Target Pair
Complement factor B (Homo sapiens (Human))	BDBM160483 (US9682968, Example-27-3a (-)) Show SMILES COC1CCN(Cc2c(cc(C)c3[nH]ccc23)C2CC2)C(C1)c1ccc(cc1)C(O)=O Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...				US Patent US9682968 (2017) BindingDB Entry DOI: 10.7270/Q2XG9P9J
					More data for this Ligand-Target Pair
Complement factor B (Homo sapiens (Human))	BDBM160272 (US9682968, Example-22-2b (-)) Show SMILES COc1cc(C)c2[nH]ccc2c1CN1CCC(C)(C)CC1c1ccc(cc1)C(O)=O Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...				US Patent US9682968 (2017) BindingDB Entry DOI: 10.7270/Q2XG9P9J
					More data for this Ligand-Target Pair
Complement factor B (Homo sapiens (Human))	BDBM160485 (US9682968, Example-27-4a (+)) Show SMILES CCOC1CCN(Cc2c(cc(C)c3[nH]ccc23)C2CC2)C(C1)c1ccc(cc1)C(O)=O Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...				US Patent US9682968 (2017) BindingDB Entry DOI: 10.7270/Q2XG9P9J
					More data for this Ligand-Target Pair
Complement factor B (Homo sapiens (Human))	BDBM159545 (US10093663, Example 17-30 | US9682968, Example-17-...) Show SMILES CCC1CCN(Cc2c(OC)cc(C)c3[nH]ccc23)C(C1)c1ccc(cc1)C(O)=O Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...				US Patent US9682968 (2017) BindingDB Entry DOI: 10.7270/Q2XG9P9J
					More data for this Ligand-Target Pair
Complement factor B (Homo sapiens (Human))	BDBM159938 (US10093663, Example 17-29 | US9682968, Example-17-...) Show SMILES COc1cc(C)c2[nH]ccc2c1CN1CCC2(CC2)CC1c1ccc(cc1)C(O)=O Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...				US Patent US9682968 (2017) BindingDB Entry DOI: 10.7270/Q2XG9P9J
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410279 (US10377770, Example 41 | US10377770, Example 42) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1cnc2c(c1)N1CCOCC1CC2(C)O Show InChI InChI=1S/C27H28F2N4O3/c1-16-4-5-19(32-25(34)17-6-7-30-23(11-17)27(3,28)29)12-21(16)18-10-22-24(31-14-18)26(2,35)13-20-15-36-9-8-33(20)22/h4-7,10-12,14,20,35H,8-9,13,15H2,1-3H3,(H,32,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410218 (US10377770, Example 11 | US10377770, Example 9) Show SMILES Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1ccc2C(O)CC3COCCN3c2c1 Show InChI InChI=1S/C26H24F3N3O3/c1-15-22(16-5-6-21-23(10-16)32-7-8-35-14-20(32)12-24(21)33)11-19(13-30-15)31-25(34)17-3-2-4-18(9-17)26(27,28)29/h2-6,9-11,13,20,24,33H,7-8,12,14H2,1H3,(H,31,34)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410299 (2-(1,1-difluoroethyl)-N-(4-methyl-3-(2,4,4a,6-tetr...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1ccc2CC3(COC3)[C@@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C29H29F2N3O3/c1-18-3-6-22(33-27(35)20-7-8-32-25(12-20)28(2,30)31)13-23(18)19-4-5-21-14-29(16-37-17-29)26-15-36-10-9-34(26)24(21)11-19/h3-8,11-13,26H,9-10,14-17H2,1-2H3,(H,33,35)/t26-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
Complement factor B (Homo sapiens (Human))	BDBM159970 (US10093663, Example 20a | US9682968, Example-20a) Show SMILES COc1cc(C)c2[nH]ccc2c1CN1CC[C@@H](C)C[C@H]1c1ccc(cc1)C(O)=O |r| Show InChI	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0100	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...				US Patent US9682968 (2017) BindingDB Entry DOI: 10.7270/Q2XG9P9J
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410355 (US10377770, Example 115) Show SMILES CCN1C(=O)[C@@H]2COCCN2c2cc(cnc12)-c1cc(NC(=O)c2ccnc(c2)C(F)(F)F)ccc1C |r| Show InChI InChI=1S/C26H24F3N5O3/c1-3-33-23-20(34-8-9-37-14-21(34)25(33)36)10-17(13-31-23)19-12-18(5-4-15(19)2)32-24(35)16-6-7-30-22(11-16)26(27,28)29/h4-7,10-13,21H,3,8-9,14H2,1-2H3,(H,32,35)/t21-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0110	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410373 (US10377770, Example 133) Show SMILES CCN1C(=O)[C@@H]2COCCN2c2cc(nnc12)-c1cc(NC(=O)c2ccnc(c2)C(F)(F)F)ccc1C |r| Show InChI InChI=1S/C25H23F3N6O3/c1-3-33-22-19(34-8-9-37-13-20(34)24(33)36)12-18(31-32-22)17-11-16(5-4-14(17)2)30-23(35)15-6-7-29-21(10-15)25(26,27)28/h4-7,10-12,20H,3,8-9,13H2,1-2H3,(H,30,35)/t20-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0110	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410360 (N-(5-((4aR,5R)-5-(Hydroxymethyl)-1,2,4,4a,5,6-hexa...) Show SMILES Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc2C[C@@H](CO)[C@@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C26H25F3N4O3/c1-15-21(10-20(12-30-15)32-25(35)16-3-2-4-19(7-16)26(27,28)29)17-9-23-22(31-11-17)8-18(13-34)24-14-36-6-5-33(23)24/h2-4,7,9-12,18,24,34H,5-6,8,13-14H2,1H3,(H,32,35)/t18-,24-/m0/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0110	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410298 (2-(1,1-difluoroethyl)-N-(4-methyl-3-(2,4,4a,6-tetr...) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1ccc2CC3(COC3)[C@H]3COCCN3c2c1 |r| Show InChI InChI=1S/C29H29F2N3O3/c1-18-3-6-22(33-27(35)20-7-8-32-25(12-20)28(2,30)31)13-23(18)19-4-5-21-14-29(16-37-17-29)26-15-36-10-9-34(26)24(21)11-19/h3-8,11-13,26H,9-10,14-17H2,1-2H3,(H,33,35)/t26-/m1/s1	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0110	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410406 (US10377770, Example 166) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cnc2C(O)C(F)(F)C3COCCN3c2c1 Show InChI InChI=1S/C25H21F5N4O3/c1-13-2-3-16(33-23(36)14-4-5-31-19(9-14)25(28,29)30)10-17(13)15-8-18-21(32-11-15)22(35)24(26,27)20-12-37-7-6-34(18)20/h2-5,8-11,20,22,35H,6-7,12H2,1H3,(H,33,36)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0110	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair
RAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E] (Homo sapiens (Human))	BDBM410392 (US10377770, Example 152) Show SMILES Cc1ccc(NC(=O)c2ccnc(c2)C(C)(F)F)cc1-c1cnc2CC3(COC3)C3COCCN3c2c1 Show InChI InChI=1S/C28H28F2N4O3/c1-17-3-4-20(33-26(35)18-5-6-31-24(10-18)27(2,29)30)11-21(17)19-9-23-22(32-13-19)12-28(15-37-16-28)25-14-36-8-7-34(23)25/h3-6,9-11,13,25H,7-8,12,14-16H2,1-2H3,(H,33,35)	PDB UniProtKB/SwissProt GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	0.0110	n/a	n/a	n/a	n/a	n/a	n/a
Novartis AG US Patent					Assay Description The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...				US Patent US10377770 (2019) BindingDB Entry DOI: 10.7270/Q25X2C9T
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 2380 total )  |  Next  |  Last  >>

Jump to: